<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899327</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000595855</org_study_id>
    <secondary_id>MRC-MDS-BIO1</secondary_id>
    <secondary_id>EU-20852</secondary_id>
    <nct_id>NCT00899327</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants</brief_title>
  <official_title>Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects, Myelodysplastic Syndromes (MDS) and Secondary Disorders of Heamatopoiesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients at risk&#xD;
      of developing myelodysplastic syndrome may help doctors learn more about changes that occur&#xD;
      in DNA and identify biomarkers related to disorders of the blood and bone marrow.&#xD;
&#xD;
      PURPOSE: This research study is looking at biomarkers in patients at risk of developing&#xD;
      myelodysplastic syndrome or other disorders and in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To identify novel biomarkers of disease that would help in the initial diagnosis of&#xD;
           myelodysplastic syndromes (MDS).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To understand the genesis of anemia in cancers.&#xD;
&#xD;
        -  To identify novel biomarkers of disease that predict progression of MDS to acute myeloid&#xD;
           leukemia.&#xD;
&#xD;
      OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and&#xD;
      progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor&#xD;
      cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is&#xD;
      extracted for molecular analyses, including gene mutation analysis, gene methylation assays,&#xD;
      chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Identification of novel biomarkers of disease</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of novel biomarkers of disease progression from myelodysplastic syndromes to acute myeloid leukemia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehension of genesis of anemia in cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Being investigated for a potential blood disorder due to abnormal blood count&#xD;
&#xD;
               -  Patients with a known blood disorder who are having a bone marrow sample taken as&#xD;
                  part of the assessment of that disorder&#xD;
&#xD;
               -  Patients undergoing hip replacement surgery at Nuffield Orthopaedic Centre,&#xD;
                  Oxford meeting the following criteria:&#xD;
&#xD;
                    -  Not on treatment likely to impair bone marrow function&#xD;
&#xD;
                    -  No history of having had treatment likely to have impaired bone marrow&#xD;
                       function&#xD;
&#xD;
                    -  Normal blood count&#xD;
&#xD;
               -  Archived samples from patients with known blood disorder&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vyas Paresh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1865-222-309</phone>
      <email>paresh.vyas@imm.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>July 7, 2009</last_update_submitted>
  <last_update_submitted_qc>July 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2009</last_update_posted>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

